Project Grant R21AI193604
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, College Park a Project Grant totaling $571,412 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 11, 2026, with a completion date of May 31, 2031. This five-year research project investigates the role of linear diribonucleotides as signaling molecules in bacterial physiology and pathogenesis. The research builds upon prior findings...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, Baltimore $849,146 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant commencing September 9, 2025, with an ultimate completion date of August 31, 2027. This research initiative focuses on advancing understanding of the molecular mechanisms governing anthrax toxin protein unfolding and transmembrane translocation across host...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, College Park $417,295 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on heme adaptation mechanisms in Group A Streptococcus (GAS). The award, issued February 23, 2026, and extending through January 31, 2028, will support an R21 project investigating how GAS senses and regulates heme levels during invasive infections such...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of Maryland, Baltimore a $463,676 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 7, 2025, with completion targeted for July 31, 2030. This research initiative will generate scientific knowledge and methodological advances focused on understanding Fc-mediated effector functions in infectious disease contexts, specifically...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, Baltimore a $678,218 Project Grant effective April 1, 2026, through March 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research award supports multi-omics analysis of bacteria-host interactions in Brugia malayi, a medically important parasitic nematode that harbors obligate Wolbachia bacterial endosymbionts. The research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $234,000 to the University of Maryland, College Park under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 26, 2026 through April 30, 2028. This Project Grant supports research aimed at deciphering phagosomal membrane repair pathways during Mycobacterium tuberculosis (MTB) infection through advanced single-cell and single-phagosome analysis methodologies. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, College Park $1.795 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a four-year project period (August 1, 2025 – July 31, 2029). The award supports development of a Phenotypically Amplified Beta-Lactamase (PHABL) assay, a rapid diagnostic tool designed to identify beta-lactam-resistant bacterial pathogens in bloodstream...
- Federal Grant Award Summary Princeton University's Office of Research and Project Administration received a $451,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2027. The research initiative employs chemical synthetic lethality methodology to identify novel antimicrobial targets in gram-negative bacterial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, Baltimore $445,488 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period from July 1, 2025 through June 30, 2027. This Project Grant supports scientific research to characterize long non-coding RNAs (lncRNAs) in Plasmodium falciparum and elucidate their roles in gene regulation. The research deliverables include...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $427,625.00 to the University of Maryland, Baltimore under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 6, 2026, for a project period extending through March 31, 2028. The award supports research aimed at modeling the vaginal microbiome to predict bacterial vaginosis (BV) recurrence and identify preventative treatment targets. The project employs whole-genome...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $421,242 to the University of Maryland Baltimore County under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning June 11, 2026, and concluding May 31, 2028. This Project Grant supports fundamental research investigating bacterial ferrous iron sensing via the BqsRS (CarRS) two-component system in Pseudomonas aeruginosa (PA), an opportunistic gram-negative pathogen responsible for significant nosocomial infections. The research aims to generate mechanistic and functional understanding of the BqsRS two-component signal transduction system at atomic, molecular, and organismal levels to enable exploitation of this system as a potential therapeutic target for reducing PA virulence, biofilm formation, and antibiotic resistance. The research deliverables will advance understanding of how PA responds to environmental iron availability through signal transduction mechanisms that regulate critical virulence factors, including rhamnolipid production and biofilm formation and dispersal. By elucidating the structure, selectivity, and mechanism of the BqsRS system, the research is intended to provide foundational knowledge supporting development of novel therapeutic strategies to mitigate the pathogenic potential of PA and other opportunistic pathogens in clinical settings.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $421.2k | 6/11/26 |